Nosis was founded to address the largest unmet need in RNA therapeutic development: cell-specific delivery.
We aspire to end chronic disease by changing the cost and risk curve of new therapeutic development.
Inspired by the Greek concept “gnosis” – the pursuit of sacred knowledge and deep insight into the true nature of humanity – we adopt a principled, knowledge-based approach to the treatment of disease.
Delivering on the potential of RNA medicines at scale.
Where traditional methods have faced significant challenges, Nosis saw an opportunity to re-think the problem from first principles. With a team of brilliant scientists and engineers across computational, biochemistry, and translational disciplines, Nosis has developed the first purpose built platform for receptor-targeted RNA development at scale.